US 12,442,824 B2
Assays for determining plasma kallikrein system biomarkers
Daniel J. Sexton, Melrose, MA (US); Ryan Faucette, Melrose, MA (US); Jon A. Kenniston, Hingham, MA (US); Gregory P. Conley, Arlington, MA (US); Andrew Nixon, Hanover, MA (US); Christopher TenHoor, Hopkinton, MA (US); and Burt Adelman, Concord, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Dec. 20, 2021, as Appl. No. 17/555,636.
Application 17/555,636 is a continuation of application No. 15/030,811, granted, now 11,372,002, previously published as PCT/US2014/061247, filed on Oct. 17, 2014.
Claims priority of provisional application 61/939,837, filed on Feb. 14, 2014.
Claims priority of provisional application 61/893,505, filed on Oct. 21, 2013.
Prior Publication US 2022/0291232 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); A61K 39/00 (2006.01); C07K 16/36 (2006.01); C07K 16/40 (2006.01); C12Q 1/37 (2006.01); C12Q 1/56 (2006.01)
CPC G01N 33/6893 (2013.01) [C07K 16/36 (2013.01); C07K 16/40 (2013.01); C12Q 1/37 (2013.01); C12Q 1/56 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12Y 304/21034 (2013.01); C12Y 304/21038 (2013.01); G01N 2333/4713 (2013.01); G01N 2333/96455 (2013.01); G01N 2333/96458 (2013.01); G01N 2500/02 (2013.01); G01N 2500/20 (2013.01); G01N 2800/224 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A method for assessing plasma activation, comprising:
providing a plasma sample from a subject;
incubating the plasma sample with an activator of plasma kallikrein (pKal), wherein the activator is Factor XIIa (FXIIa) and wherein the activator is added ex vivo; and
measuring the level of cleaved high molecular weight kininogen (HMWK) in the plasma sample after ex vivo activation;
wherein the subject has been treated with a pKal inhibitor.